top of page
100.jpg

Superficial Radiation Theraphy

srt100.jpg

By delivering a precise, calibrated dose of Superficial Radiation Therapy that only goes skin deep, patients can be safely treated right in their physician’s office. Each treatment is virtually painless.

​

Low-dose Superficial Radiation Therapy effectively destroys basal cell carcinoma and squamous cell carcinoma, as well as the non-malignant tumor cells that cause keloids. Best of all, it doesn’t involve cutting, bleeding or stitching. With the SRT-100™, there is no need for anesthesia, minimal risk of infection or scarring, no need for reconstructive plastic surgery. Patients heal quickly and don’t have downtime or lifestyle restrictions following treatment.

​

Sensus Healthcare’s SRT-100™ has been cleared by the U.S. Food and Drug Administration for the treatment of non-melanoma skin cancer and keloids. It is ideal for private dermatology and oncology practices, as well as hospitals and multi-locale healthcare providers.

Superficial Radiation Theraphy offers hope to keloid sufferers.

SRT safety destroys the cells that form keloids, with over a 94% cure rate when used in combination with surgery. The SRT-100, SRT-100+ and SRT-100 Vision are FDA cleared for the treatment of keloids following surgical removal. Offering a keloid cure serves as an ideal base on which to build a strong footprint in the ethnic community. 

Sensus_PMK_KeloidImages8.png
bottom of page